Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aravive, Inc.VSAR · Entity 114535 | Chief Medical Officer | December 20, 2017 | December 22, 2017 |
| uniQure N.V.QURE · Entity 4162 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aravive, Inc.
Report date December 20, 2017 · Filed December 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 227,300 |
Reported balance
After 2017-12-20 transaction · row 1
1 source rowRow 1 · 2017-12-20 · Grant · Acquired 91,300 · Balance 227,300 F1: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares vest on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares vest on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20, 2021.
uniQure N.V.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 32,259 |
Ending reported balance
After 2026-06-11 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-06-10 · Exercise / conversion · Acquired 2,645 · Balance 34,987 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Row 2 · 2026-06-10 · Sale · Disposed 2,645 · Balance 32,342 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.53. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Row 3 · 2026-06-10 · Sale · Disposed 3,127 · Balance 29,215 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.18. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Row 4 · 2026-06-10 · Sale · Disposed 1,780 · Balance 27,435 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.14 . The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Row 5 · 2026-06-10 · Grant · Acquired 7,550 · Balance 34,985 F5: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Row 6 · 2026-06-11 · Sale · Disposed 2,726 · Balance 32,259 F6: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.04 · Expires 2032-02-24 | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-06-10 · Exercise / conversion · Disposed 2,645 · Balance 0 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F8: The Stock Option vested in full on February 24, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.82 · Expires 2036-06-10 | Direct | 13,980 |
Reported balance
After 2026-06-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-06-10 · Grant · Acquired 13,980 · Balance 13,980 F9: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.53. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.18. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.14 . The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F5: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
F6: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F8: The Stock Option vested in full on February 24, 2023.
F9: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 22:04 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,726 | $27.06 | $73,765.56 |
DisclosureSEC source: 0000904454-26-000350 · edgar.xml · nonDerivative · entry 6 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,259 F6 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F6 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:04 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 13,980 | $0.00 Strike: $26.82 | $0.00 |
DisclosureSEC source: 0000904454-26-000350 · edgar.xml · derivative · entry 8 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,980 Underlying: Ordinary Shares · 13,980 shares Expires 2036-06-10 F9 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:04 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,645 | $0.00 Strike: $16.04 | $0.00 |
DisclosureSEC source: 0000904454-26-000350 · edgar.xml · derivative · entry 7 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,645 shares Expires 2032-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F8 · derivative.exercise_date: The Stock Option vested in full on February 24, 2023. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:04 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 7,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-26-000350 · edgar.xml · nonDerivative · entry 5 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,985 F5 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:04 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,780 | $26.05 | $46,369.00 |
DisclosureSEC source: 0000904454-26-000350 · edgar.xml · nonDerivative · entry 4 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,435 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.14 . The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:04 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 3,127 | $26.03 | $81,395.81 |
DisclosureSEC source: 0000904454-26-000350 · edgar.xml · nonDerivative · entry 3 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,215 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.18. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:04 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,645 | $26.07 | $68,955.15 |
DisclosureSEC source: 0000904454-26-000350 · edgar.xml · nonDerivative · entry 2 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,342 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.53. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:04 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 2,645 | $16.04 | $42,425.80 |
DisclosureSEC source: 0000904454-26-000350 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:26 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,810 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000904454-26-000021 · edgar.xml · derivative · entry 5 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,810 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The Stock Option vested in full on June 15, 2023. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:26 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 7,803 | $25.09 | $195,777.27 |
DisclosureSEC source: 0000904454-26-000021 · edgar.xml · nonDerivative · entry 4 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,342 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:26 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 500 | $25.03 | $12,515.00 |
DisclosureSEC source: 0000904454-26-000021 · edgar.xml · nonDerivative · entry 3 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,145 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.02 to $25.04. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:26 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 17,310 | $24.39 | $422,190.90 |
DisclosureSEC source: 0000904454-26-000021 · edgar.xml · nonDerivative · entry 2 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,645 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.02 to $25.00. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:26 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 17,810 | $14.08 | $250,764.80 |
DisclosureSEC source: 0000904454-26-000021 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 21:54 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,840 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000904454-25-000568 · edgar.xml · derivative · entry 4 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,840 shares Expires 2034-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The Stock Option vested in full on June 19, 2025. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 21:54 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 15,594 | $27.30 | $425,716.20 |
DisclosureSEC source: 0000904454-25-000568 · edgar.xml · nonDerivative · entry 3 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,145 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 21:54 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 15,840 | $27.22 | $431,164.80 |
DisclosureSEC source: 0000904454-25-000568 · edgar.xml · nonDerivative · entry 2 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,739 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.00 to $27.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 21:54 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 15,840 | $4.57 | $72,388.80 |
DisclosureSEC source: 0000904454-25-000568 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Adjusted to reflect (i) the sale of 1,120 shares under the Reporting Person's 10b5-1 plan on June 23, 2020, which was inadvertently omitted from the Form 4 filed on June 24, 2020, and (ii) the correction to a typographical error in the number of shares sold by the Reporting Person on June 13, 2024 reported on the Form 4 filed on June 17, 2024. The Form 4 reported the sale of 3,504 shares but should have reported the sale of 3,524 shares. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 21:45 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 3,336 | $14.45 | $48,205.20 |
DisclosureSEC source: 0000904454-25-000332 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,879 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.40 to $14.50. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:50 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 15,630 | $0.00 Strike: $16.22 | $0.00 |
DisclosureSEC source: 0000904454-25-000311 · edgar.xml · derivative · entry 2 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,630 Underlying: Ordinary Shares · 15,630 shares Expires 2035-06-11 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:50 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 7,970 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-25-000311 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,215 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:19 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 15,840 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000904454-24-000407 · edgar.xml · derivative · entry 2 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,840 Underlying: Ordinary Shares · 15,840 shares Expires 2034-06-19 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:19 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-24-000407 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,245 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 23:19 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 3,504 | $5.12 | $17,940.48 |
DisclosureSEC source: 0000904454-24-000367 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,165 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.12 to $5.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:20 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 3,228 | $18.88 | $60,944.64 |
DisclosureSEC source: 0000904454-23-000394 · edgar.xml · nonDerivative · entry 2 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,669 F3 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F3 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.85 to $18.92. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 20, 2023 21:20 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 17,060 | $0.00 Strike: $20.18 | $0.00 |
DisclosureSEC source: 0000904454-23-000394 · edgar.xml · derivative · entry 3 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,060 Underlying: Ordinary Shares · 17,060 shares Expires 2033-06-13 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 13, 2023 Filed Jun 20, 2023 21:20 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-23-000394 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,897 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 21:09 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,431 | $21.16 | $30,279.96 |
DisclosureSEC source: 0000899243-23-006569 · doc4.xml · nonDerivative · entry 2 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,197 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:09 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 537 | $19.79 | $10,627.23 |
DisclosureSEC source: 0000899243-23-006569 · doc4.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,628 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. 530 of the shares were sold in multiple transactions at prices ranging from $19.65 to $19.99 and 7 of the shares were sold at $20.86. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:46 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 17,810 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000904454-22-000358 · edgar.xml · derivative · entry 2 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,810 Underlying: Ordinary Shares · 17,810 shares Expires 2032-06-15 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:46 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 9,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000358 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,165 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:41 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,602 | $16.70 | $26,753.40 |
DisclosureSEC source: 0000904454-22-000201 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,085 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.70 to $16.81. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:02 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 2,645 | $0.00 Strike: $16.04 | $0.00 |
DisclosureSEC source: 0000904454-22-000175 · edgar.xml · derivative · entry 2 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,645 Underlying: Ordinary Shares · 2,645 shares Expires 2032-02-24 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:02 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 1,534 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000175 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,687 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 22:08 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,348 | $18.12 | $42,545.76 |
DisclosureSEC source: 0000904454-22-000073 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,153 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.95 to $18.16. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 13:32 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 4,500 | $36.61 | $164,745.00 |
DisclosureSEC source: 0000904454-21-000678 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,501 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.44 to $36.84. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 19:23 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,300 | $36.98 | $48,074.00 |
DisclosureSEC source: 0000904454-21-000295 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,001 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.60 to $36.98. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:36 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 4,107 | $0.00 Strike: $37.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000267 · edgar.xml · derivative · entry 2 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,107 Underlying: Ordinary Shares · 4,107 shares Expires 2031-02-25 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:36 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 2,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000267 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,301 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 15:49 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 604 | $39.09 | $23,610.36 |
DisclosureSEC source: 0000904454-21-000078 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,919 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.94 to $39.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2020 Filed Sep 22, 2020 13:48 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 4,352 | $39.12 | $170,250.24 |
DisclosureSEC source: 0000904454-20-000624 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,523 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.84 to $39.72. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 20:21 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,875 | $0.00 Strike: $39.97 | $0.00 |
DisclosureSEC source: 0000904454-20-000417 · edgar.xml · derivative · entry 5 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,125 Underlying: Ordinary Shares · 21,875 shares Expires 2028-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Option vests over four years, with 25% vesting after twelve months from the date of grant (09/18/2018) and then 6.25% every three months thereafter, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 20:21 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $35.40 | $0.00 |
DisclosureSEC source: 0000904454-20-000417 · edgar.xml · derivative · entry 4 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires 2028-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Stock Option vests over three years, with one-third vesting after twelve months from the date of grant (06/14/2018) and then one-twelfth every three months thereafter, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 20:21 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 26,875 | $70.00 | $1,881,250.00 |
DisclosureSEC source: 0000904454-20-000417 · edgar.xml · nonDerivative · entry 3 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,875 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 20:21 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 21,875 | $39.97 | $874,343.75 |
DisclosureSEC source: 0000904454-20-000417 · edgar.xml · nonDerivative · entry 2 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 20:21 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 5,000 | $35.40 | $177,000.00 |
DisclosureSEC source: 0000904454-20-000417 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 21:05 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 21,719 | $0.00 Strike: $51.81 | $0.00 |
DisclosureSEC source: 0000904454-20-000269 · edgar.xml · derivative · entry 2 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,719 Underlying: Ordinary Shares · 21,719 shares Expires 2030-02-27 F2 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 21:05 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 12,380 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000269 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,875 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| January 31, 2020 Filed Jan 31, 2020 21:17 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 5,610 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000136 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,495 F1 · shares: Represents performance-based restricted share units ("PRSUs") granted on January 25, 2019 to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated, which vested on January 31, 2020. Each PRSU represents the contingent right to receive one Ordinary Share. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 23:02 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 596 | $62.19 | $37,065.24 |
DisclosureSEC source: 0000904454-20-000090 · edgar.xml · nonDerivative · entry 2 Gut Robert · CIK 0001716268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,885 F2 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 23:02 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 6,897 | $60.01 | $413,888.97 |
DisclosureSEC source: 0000904454-20-000090 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,481 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.